One of the most counterintuitive patterns observed in the technical review of public-backed credit operations — PRONAMPE, FGI-PEAC, BNDES Automático — is that, even when the bank already has 80% of the credit risk covered by a state guarantee fund, a meaningful share of the operations reviewed still carries an ancillary product the company never asked for and, in most cases, had no real freedom to decline: loan-linked life insurance or a capitalization bond.
In this analysis
A "zero-risk" credit that still comes with mandatory insurance
The commercial logic behind this is well known and has a name in legal literature: tied selling. Brazil's Superior Court of Justice already settled the issue in Repetitive Precedent 972, which specifically addresses the abusiveness of tied selling of insurance in credit operations, and the practice of conditioning a credit approval on the purchase of an ancillary financial product is barred under article 39, item I, of the Consumer Protection Code — which prohibits conditioning the supply of one product or service on the purchase of another, absent a technical or legal justification.
The pattern identified in the forensic sample
Within the set of business credit operations reviewed technically, tied selling of insurance or a capitalization bond appears in roughly a quarter of the cases — all of them linked to fomento or working-capital lines with real collateral. A few examples illustrate the pattern, always treated here in aggregate and anonymized form:
A backdated policy. In a working-capital operation through a credit union, tied selling of loan-linked insurance was identified with a policy backdated to a period before the credit note itself was even issued — evidence that the insurance was inserted into the product's structure after the fact.
Life insurance financed with no option to decline. In an FGI-PEAC-backed operation, the bank sold a three-year business life insurance policy, with a premium equal to over 10% of the total credit amount, with no recorded option to decline — and financed that premium inside the loan's own principal.
Insurance naming the bank itself as beneficiary. In another FGI/PEAC-backed operation with a fiduciary assignment of a CD, loan-linked insurance was identified naming the lending bank itself as the beneficiary — a structure in which the ancillary product primarily protects the seller's interest, not the buyer's.
A capitalization bond withholding 10%. In an FGI-PEAC working-capital operation, tied selling of a capitalization bond was identified, withholding an amount equal to 10% of the operation's value — a use expressly barred by the emergency program's own regulation.
Did your public-backed credit come with insurance or a capitalization bond baked in?
Request a preliminary technical screening to check for tied selling and its impact on your CET.
Why this is technically serious, not just "abusive"
From a strictly technical-financial standpoint, tied selling in public-backed credit produces three concrete effects beyond the moral discomfort of the imposition:
First, it inflates the Total Effective Cost (CET) without transparent disclosure. In more than one case in the sample, the disclosed CET was numerically identical to the nominal interest rate — a mathematical impossibility whenever any ancillary charge is embedded in the operation, such as a fee, financed excise tax, or insurance premium.
Second, it generates compound interest on a cost that shouldn't be part of the principal. When the insurance premium or the capitalization bond's value is financed within the same credit instrument, it gets amortized on the same interest schedule as the loan — and, if there's a capitalizing grace period, the insurance premium grows alongside the working-capital balance, multiplying its real cost over the life of the contract.
Third, it contradicts the fomento program's own logic. If the emergency line's stated goal is to make credit access cheaper for companies in distress, bundling in an unsolicited insurance or capitalization product — whose only immediate financial effect is to shrink the net amount disbursed and grow the balance that accrues interest — runs opposite to the purpose of the public subsidy underpinning the line.
What to check before signing
For a business owner in the process of contracting fomento credit, a few objective points deserve extra attention:
- Request in writing an itemized list of every ancillary product embedded in the contract and its cost in currency, not just as a percentage.
- Explicitly ask whether the insurance purchase is a condition for credit disbursement — if it is, that's already an indicator of tied selling barred under Precedent 972.
- Check whether the disclosed CET includes the insurance cost by comparing it with the stated nominal rate.
- Remember: the law governing PRONAMPE itself expressly bars charging fees and extraordinary charges beyond what the program provides for.
This article is part of a series on technical pathologies in business credit operations, based on expert opinions prepared by the author. Individual cases are treated in aggregate and anonymized form, with no identification of the companies or individuals involved.
Frequently asked questions
What is tied selling in a business credit contract?
It's the practice of conditioning a credit approval on the purchase of an ancillary financial product — such as loan-linked insurance or a capitalization bond — without the client having a real ability to decline. It's barred under article 39, item I, of Brazil's Consumer Protection Code.
What did Brazil's Superior Court of Justice rule about tied selling of insurance in credit operations?
In Repetitive Precedent 972, Brazil's Superior Court of Justice settled that tied selling of insurance in credit operations is abusive, recognizing that conditioning credit disbursement on purchasing insurance, with no real option to decline, violates the Consumer Protection Code.
Why does tied selling inflate the Total Effective Cost (CET) without transparency?
Because when the disclosed CET is numerically identical to the nominal interest rate, that's a mathematical impossibility whenever any ancillary charge is embedded in the operation — such as an insurance premium or a capitalization bond financed within the credit.
How do I spot tied selling before signing a public-backed credit line?
Request in writing an itemized list of every ancillary product embedded in the contract and its cost in currency, explicitly ask whether the insurance purchase is a condition for credit disbursement, and compare the disclosed nominal rate against the CET — if they're identical and an ancillary product was sold, that's a technical inconsistency worth challenging.
Dr. Lincoln Sposito
Specialist in banking audits and financial forensics, combining the statistical rigor of data science with the analysis of banking-system architectures to dismantle predatory charges against SMEs. Learn more about the expert →